Developing a new antibiotic to fight drug-resistant bacteria
A new class of antibiotic to address Antimicrobial Resistance
This study is working on new antibiotics to help fight tough bacteria that don't respond to regular treatments, aiming to create safe and effective options for people who need them.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curza INC NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project ID | NIH-11081814 on NIH RePORTER |
What this research studies
This research focuses on creating a new class of antibiotics specifically designed to combat multidrug-resistant Gram-negative bacteria, such as Acinetobacter baumannii. The approach involves developing compounds that bind to a unique site on the bacterial ribosome, which is not targeted by existing antibiotics, thereby avoiding cross-resistance. By re-engineering a natural product, the researchers aim to produce antibiotics that are effective against these resistant pathogens while being safe for human cells. The project will advance a promising antibiotic candidate through critical testing stages.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by multidrug-resistant Gram-negative bacteria.
Not a fit: Patients with infections caused by non-resistant bacteria or those not infected may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from infections caused by antibiotic-resistant bacteria.
How similar studies have performed: Other research has shown promise in developing antibiotics targeting unique bacterial sites, indicating potential for success in this novel approach.
Where this research is happening
Salt Lake City, UNITED STATES
- Curza INC — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Testa, Charles — Curza INC
- Study coordinator: Testa, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.